Max T.
- Country
- Germany
- Department
- Medical Polyclinic II
Research Overview
- Safety and Dosing Evaluation of KITE-363 and KITE-753 in Relapsed/Refractory B-cell Lymphoma Patients
- Safety and Tolerability Assessment of Odronextamab in Patients with CD20-Positive B-Cell Non-Hodgkin Lymphoma
- Phase I/II Study on Safety and Efficacy of AZD5492 as Monotherapy and in Combination for Relapsed/Refractory B-Cell Malignancies
Data & Insights
Has run more than one trial at 148 of 324 partner sites.
Specializations
Lymphoma Research
Focused on innovative treatments for various forms of lymphoma, particularly B-cell lymphomas and Hodgkin lymphoma. Investigates novel therapeutic approaches including CAR-T cell therapy and targeted immunotherapy combinations.
- Mantle Cell Lymphoma
- Large B-Cell Lymphoma
- Follicular Lymphoma
- Classical Hodgkin Lymphoma
Leukemia Studies
Specializes in developing treatments for acute lymphoblastic leukemia, with particular emphasis on Philadelphia-chromosome positive ALL. Explores combination therapies including tyrosine kinase inhibitors and targeted antibody treatments.
- B-Cell Acute Lymphoblastic Leukemia
- Chronic Lymphocytic Leukemia
- Philadelphia-Positive ALL
Immunotherapy Applications
Leads research in novel immunotherapy approaches for hematologic malignancies, including studies of checkpoint inhibitors and antibody-based therapies. Investigates innovative treatment combinations for refractory and relapsed conditions.
- CAR-T Cell Therapy
- Targeted Antibody Treatments
- EBV-Positive Lymphomas
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.